SVA Architects and Inland Empire Health Plan Celebrate Completion of Campus Transformation

One of Region’s Largest Employers Receives New Training and Fitness Facilities

SANTA ANA, Calif., Sept. 29, 2020 /PRNewswire/ — SVA Architects joins Inland Empire Health Plan (IEHP) in celebrating the completion of IEHP’s reimagining of their Rancho Cucamonga campus. IEHP is the largest not-for-profit Medi-Cal and Medicare health plan in the Inland Empire, and one of the largest employers in the region. With a provider network of 6,954, IEHP provides quality, accessible healthcare services to more than 1.3 million members in San Bernardino and Riverside Counties. The transformation of the IEHP campus includes renovating an existing office building to feature the new Center for Learning and Development, as well as a large health and fitness center and ancillary office function. Located at 9500 Cleveland Avenue in Rancho Cucamonga, the project created one of the largest employee training centers in the Inland Empire and in California.

The interior

Read More

InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

VANCOUVER, BC, Sept. 24, 2020 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced that all subjects participating in its second Phase 1 clinical trial with INM-755 have completed treatment. INM-755 is being developed as a topical CBN-based cream to potentially treat Epidermolysis Bullosa (“EB”) as well as potentially other dermatological diseases.

The 755-102-HV clinical trial is a randomized, double-blind, vehicle-controlled, Phase 1 study designed to evaluate the safety and tolerability of INM-755 cream applied daily on epidermal wounds in healthy volunteers. Eight adult subjects were treated with two strengths of INM-755 cream over a 14-day treatment period. As with InMed’s first Phase 1 clinical trial with INM-755, the 755-102-HV trial is being conducted at the Centre for Human

Read More